Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

RNA-seq of SARS-CoV-2-infected human primary hepatocyte-derived spheroids upon interferon a2 and baricitinib treatment

ABSTRACT: RNA-seq of SARS-CoV-2-infected human primary hepatocyte-derived spheroids upon interferon a2 and baricitinib treatment

PROVIDER: PRJEB41026 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	ERR4777050_1.fastq.gz	Fastqsanger.gz
	ERR4777050_2.fastq.gz	Fastqsanger.gz
	ERR4777051_1.fastq.gz	Fastqsanger.gz
	ERR4777051_2.fastq.gz	Fastqsanger.gz
	ERR4777052_1.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 24

Similar Datasets

RNA-seq of SARS-CoV-2-infected human primary hepatocyte-derived spheroids upon interferon a2 and baricitinib treatment

Project description:Biological replicates of liver spheroids derived from primary hepatocytes were treated with IFNa2 and/or baricitinib for 24 h and subsequently infected with Sars-CoV-2. The cells were harvested 48 h time after infection. Total RNA was extracted and sequenced with a strand-specific paired end RNA-seq protocol.

2020-11-18 | E-MTAB-9711 | biostudies-arrayexpress

E-MTAB-9711

Project description:RNA-seq of SARS-CoV-2-infected human primary hepatocyte-derived spheroids upon interferon a2 and baricitinib treatment

2025-01-23 | E-MTAB-9711 | ExpressionAtlas

Cold Storage of Rat Hepatocyte Spheroids

Project description:The purpose of this study was to optimize conditions for cold storage of rat hepatocyte spheroids without freezing. Rat hepatocytes were isolated by a two-step perfusion method; hepatocyte spheroids were formed during 48 h of rocked culture in serum-free medium (SFM). Spheroids were then maintained in rocked culture at 37°C (control condition) or cold stored at 4°C for 24 or 48 h in six different cold storage solutions: SFM alone; SFM + 1 mM deferoxamine (Def); SFM + 1 ?M cyclosporin A (CsA); SFM + 1 mM Def + 1 ?M CsA, University of Wisconsin (UW) solution alone, UW + 1 mM Def.

2015-05-14 | ST000167 | MetabolomicsWorkbench

Hepatocyte thorns, a novel drug-induced stress response in human and mouse liver spheroids

Project description:The in vivo-relevant phenotype of 3D liver spheroids allows for long-term studies of e.g. novel mechanisms of chronic drug-induced liver toxicity. Using this system, we present a novel drug-induced stress response in human and murine hepatocyte spheroids wherein long slender filaments form after chronic treatment with four different drugs, of which, three are PPARα an-tagonists. The morphology of the thorns varies between donors and compounds used. They are mainly composed of diverse protein fibres, which are glycosylated. Their formation is inhibited by treatment with fatty acids or antioxidants. Treatment of mice with GW6471, revealed changes in gene and protein expression like those in the spheroids. In addition, similar changes in kera-tin expression were seen following treatment of hepatotoxic drugs including aflatoxin B1, para-cetamol, chlorpromazine, cyclosporine and ketoconazole. We suggest that thorn formation may be indicative of hepatocyte metaplasia in response to toxicity and that more focus should be placed on alterations of ECM derived protein expression as biomarkers of liver disease and chronic drug-induced hepatotoxicity, changes that can be studied in stable in vivo-like hepatic cell systems like the spheroids.

2022-05-26 | PXD033550 | Pride

PolyA-enriched RNA-seq of primary human hepatocyte spheroids treated with small molecule inhibitors targeting TEAD

Project description:TEAD1 emerged as an estrogen-sensitive gene that was upregulated in a HFD mouse model and in NAFLD patients. We investigated the roles of TEAD in NAFLD by treating primary human hepatocyte spheroids with two small molecule inhibitors blocking the TEAD/YAP interaction. One small molecule blocks the interaction by inhibiting TEAD autopalmitoylation (TEADap), the second small molecule blocks the interaction by binding to the surface of the TEAD protein (TEADsf).

2024-02-22 | E-MTAB-13207 | biostudies-arrayexpress

Induced Hepatocyte-Like Cells with Interferon timecourse

Project description:This experiment investigates the transcriptional effect of Interferon Alpha or Interferon Lambda upon Induced Hepatocyte-Like Cells (iHLCs). Peginterferon lambda-1a (Lambda) is a type III interferon that acts through a unique receptor complex expressed primarily on hepatocytes. In Phase 2b clinical studies, a combined regimen of Lambda with ribavirin (RBV) was associated with more rapid declines in viral load compared to a peginterferon alfa (PEGASYS; alfa) plus RBV regimen. This correlated with improved virologic response rates at Weeks 4 and 12 of treatment. To gain insight into the potential molecular mechanisms of these early robust responses with Lambda, we investigated the effects of alfa and Lambda on transcription in iHLCs obtained from Cellular Dynamics.. These samples are a subset of a larger experiment to be published at a later date.

2015-01-31 | E-MTAB-2477 | biostudies-arrayexpress

Label-free proteomic analysis of hepatocyte spheroids fed physiologically relevant levels of palmitic acid and oleic acid to mimic non-alcoholic fatty liver disease.

Project description:We have grown hepatocyte spheroids for 21 days following an established protocol. We have carried out proteomic analysis of the difference between control and treated (Fatty acids) spheroids during seven days (5 timepoints at day 0, 1, 2, 4 and 7). Samples were digesting using filter aided sample preparation-based digestion and subsequently analysed using label free LC-MS/MS.

2021-11-24 | PXD029200 | Pride

Treatment of C3H/HeJ grafted mice with baricitinib [prevention]

Project description:The C3H/HeJ grafted model of alopecia areata was used to determine the efficacy of systemic baricitinib at preventing alopecia or treating established disease. The efficacy of topical baricitinib at treating established alopecia in the C3H/HeJ grafted model was also assessed. Microarrays were performed on skin RNA at week 0 and week 12 after starting treatment in all models. Baricitinib was administered in systemic form at the time of grafting. Skin samples were taken after 12 weeks.

2015-05-01 | E-GEOD-61551 | biostudies-arrayexpress

Treatment of C3H/HeJ grafted mice with baricitinib [systemic]

Project description:The C3H/HeJ grafted model of alopecia areata was used to determine the efficacy of systemic baricitinib at preventing alopecia or treating established disease. The efficacy of topical baricitinib at treating established alopecia in the C3H/HeJ grafted model was also assessed. Microarrays were performed on skin RNA at week 0 and week 12 after starting treatment in all models. Baricitinib was administered in systemic form after disease establishment. Skin samples were taken at the start of treatment and after 12 weeks.

2015-05-01 | E-GEOD-61552 | biostudies-arrayexpress

Treatment of C3H/HeJ grafted mice with baricitinib [topical]

Project description:The C3H/HeJ grafted model of alopecia areata was used to determine the efficacy of systemic baricitinib at preventing alopecia or treating established disease. The efficacy of topical baricitinib at treating established alopecia in the C3H/HeJ grafted model was also assessed. Microarrays were performed on skin RNA at week 0 and week 12 after starting treatment in all models. Baricitinib was administered in topical form after disease establishement. Skin samples were taken at the start of treatment and after 12 weeks.

2015-05-01 | E-GEOD-61554 | biostudies-arrayexpress

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data